Lanmu Medical Completes Nearly RMB 100 Million Series A Funding Round; 10 Categories of Medical Consumables See Revised Procurement Rules

1. Three Continuous Updates on the "3+N" Alliance Joint Procurement in the Beijing-Tianjin-Hebei Region

Recently, the coronary artery category list of the "3+N" Alliance in the Beijing-Tianjin-Hebei region has been updated intensively. The Jilin Provincial Government Procurement Center issued consecutive execution notices shortly after the New Year. Starting from January 6, the coronary artery expansion balloon category will be executed according to the relevant list (version 20251222), with 7,120 items declared and 6,623 items selected. On the same day, the coronary artery guiding wire category will be executed according to two versions of the list (versions 20251022 and 20251222), with declarations of 2,164 and 13,718 items respectively, and selections of 2,148 and 13,119 items. This threefold update of the coronary consumables list resulted in the selection of a total of over 21,000 products. The intensive updates of the "balloon + guidewire" dual categories and triple-version lists form a "combination punch" for the expansion of centralized procurement, reflecting the scale effect of volume-based procurement and the trend towards refined management. This accelerates cost reduction for medical consumables benefiting the public in 2026 and provides a replicable model for national alliance procurement. (Eshare Medical Device News)

2. Tianjin Advances Reform of Medical Device Review and Approval System

Recently, the Tianjin Municipal Commerce Bureau and the Administrative Committee of the China (Tianjin) Pilot Free Trade Zone jointly released the "Implementation Plan of Tianjin on Replicating and Promoting the Pilot Measures for Fully Aligning with International High-standard Economic and Trade Rules to Advance High-level Institutional Opening-up in the Free Trade Zone." In terms of healthcare, it mentioned: advancing the reform of the medical device review and approval system, standardizing pre-review guidance for Class II medical devices, and supporting the innovation and development of medical devices such as "AI + medical devices" entering Tianjin’s special review process for innovative Class II medical devices. It also emphasized promoting the "digital strengthening of the industrial chain" in the biopharmaceuticals sector, deepening the empowerment of pharmaceutical R&D through AI technology, and improving the methods and requirements for foreign enterprises to participate in AI-driven innovation cooperation in areas like innovative drug development. (Tianjin Municipal Commerce Bureau)

3. Chongqing Releases the "Chongqing Implementation Plan for Promoting the Integration of Real and Digital Economies and Driving 'Artificial Intelligence + Manufacturing'"

Recently, the Chongqing Municipal Commission of Economy and Informatization released the "Chongqing Implementation Plan for Promoting the Integration of Real and Digital to Drive 'Artificial Intelligence + Manufacturing'". The plan mentions: making full use of AI technology to empower industrial development, accelerating the intelligent R&D and supply management of biomedicine and smart medical equipment; promoting the integration of AI technology in smart medical equipment and other industrial products and equipment to achieve intelligent upgrades and functional iterations; strengthening the application of AI in areas such as intelligent drug screening, molecular structure prediction, clinical trial design and intelligent analysis, and optimization of drug synthesis processes, developing high-value specialty raw materials, innovative small molecule drugs, antibody drugs, cell and gene therapies, new vaccines, long-acting peptide drugs, and expediting the R&D of innovative drugs; enhancing the research and application of multi-modal medical data fusion analysis, few-shot learning, and vertical large models in oncology and pathology diagnosis, and developing smart medical equipment such as AI-assisted diagnosis and treatment, intelligent pathological analysis, hemodialysis and surgical power devices, brain-computer interfaces, and wearable devices. (Chongqing Municipal Commission of Economy and Informatization)

4, 10 Categories of Medical Consumables Procurement Rules Changed

Recently, the Jiuquan Medical Insurance Bureau in Gansu released a draft consultation document for the centralized volume-based procurement of ten categories of general medical consumables through an alliance. Compared with the draft released on December 2, the procurement categories remain unchanged, but the maximum valid bid price has been removed, and there are changes in the proposed selection rules and allocation of agreed procurement volumes. The procurement entities are all public medical institutions in Jiuquan City, with a procurement cycle of two years. Companies will submit bids according to the secondary directory, with only one price allowed per competitive unit. Different products from the same company under the same registration certificate must be bid separately, though simultaneous bidding is allowed under specific circumstances. The number of proposed winning companies will depend on the number of valid bidders. A company’s bid price should not exceed the lowest purchase price within municipal medical institutions, the lowest listed price on provincial platforms, or the lowest winning bid price in regional procurements across China to be considered as a potential winner. The agreed procurement volume of selected products will be allocated based on ranking, and medical institutions may prioritize the use of the lowest-priced winning product or make independent choices for remaining volumes. (Medical Device Distributors Alliance)

5. United Imaging Joins the Billion-Dollar Surgical Robot Arena

Recently, Wuhan United Imaging Zhirong Medical Technology Co., Ltd.'s thoracoabdominal endoscopic surgical system has been approved, officially entering the competition in the field of endoscopic surgical robots. For a long time, the global endoscopic surgical robot market has been dominated by giants such as Intuitive Surgical's da Vinci system and Medtronic's HUGO. From January to November 2025, Intuitive Surgical accounted for 67.90% of the Chinese market with 55 units sold. Chinese brands such as Jinfeng Medical and MicroPort have achieved bulk sales with unit prices gradually approaching those of imported brands. United Imaging Zhirong, established in 2019, focuses on "imaging guidance" as the core to build a surgical robot product matrix. After its endoscopic surgical robot received approval, it achieved commercial layout in two major segments of the surgical robot market. Its endoscopic surgical robot realizes technological innovations in "3D perception + intelligent collaboration," making breakthroughs in imaging, operation, and efficiency. Moreover, all core components are fully self-developed and 100% localized in China. (MedTrend)

6. Tianchen Medical and Inspur Digital Technology Sign Strategic Cooperation Agreement

Recently, Tianchen Medical announced that it has signed a "Strategic Cooperation Agreement" with Inspur Digital Technology (Shanghai) Co., Ltd. (Inspur Digital) to jointly promote the innovative application and industrial implementation of intelligent and informational medical technologies in areas such as smart manufacturing of medical devices and consumables, and the research and production of medical robots. This agreement marks an important step in implementing Tianchen Medical’s dual-engine strategy: “Minimally invasive capabilities driven by end-effector components + an intelligent surgical robot ecosystem supported by the MA platform.” The partnership holds significant long-term importance, establishing a strategic cooperative relationship that provides a framework for future project collaborations, facilitating industrial integration and mutual benefit. (Sina)

7. What is the medical device public service platform?

The Medical Device Public Service Platform is jointly developed by the Oshine Group with local governments, parks, medical institutions, and research universities. It focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device technology projects. By establishing a scientific research and transfer mechanism that aligns with international standards and implementing an open and shared operation model, it attracts top-tier scientific researchers, doctors, and innovators from around the world to join. The platform provides comprehensive industry technical services including R&D transformation, incubation, and investment, fostering innovative medical device achievements with significant innovation and application value. This effort strongly supports the development of the medical device industry and technological innovation. (Compiled by Oshine)

8. Purevision Medical Completes Nearly 100 Million Yuan in Series A Financing

Recently, Suzhou Purevision Medical Technology Co., LTD. has completed a nearly RMB 100 million Series A financing round. The investment institutions and financial advisors remain undisclosed. Established in 2020, the company is a technology-driven startup focusing on innovative ophthalmic medical devices, committed to building a pioneering minimally invasive treatment platform for ophthalmology. Its self-developed AqueFish® Glaucoma Drainage Stent System fills a niche gap in China, with its core product demonstrating excellent safety and efficacy in early clinical observations. Additionally, the company has developed a series of innovative ophthalmic devices, covering surgical needs for glaucoma patients at all stages while expanding into other ophthalmic treatment markets such as dry eye and cataracts. This round of financing will primarily be used for clinical follow-ups and registration applications of core products, construction of industrial production bases, establishment of market promotion teams, and further research and development of subsequent product pipelines. (Investment界)